Kidney Fibrosis - Renal Disorders

Relevant Publications

Dihydromyricetin ameliorates diabetic renal fibrosis via regulating SphK1 to suppress the activation of NF-κB pathway.

Issue Release: 2024

Clonal hematopoiesis of indeterminate potential contributes to accelerated chronic kidney disease progression.

Issue Release: 2024

Sodium Tungstate (NaW) Decreases Inflammation and Renal Fibrosis in Diabetic Nephropathy.

Issue Release: 2024

SARS-CoV-2-related peptides induce endothelial-to-mesenchymal transition in endothelial capillary cells derived from different body districts: focus on membrane (M) protein.

Issue Release: 2024

Src inhibition modulates AMBRA1-mediated mitophagy to counteract endothelial-to-mesenchymal transition in renal allograft fibrosis.

Issue Release: 2024

Cardiotrophin-1 therapy reduces disease severity in a murine model of glomerular disease.

Issue Release: 2024

Plasma and platelet lipidome changes in Fabry disease.

Issue Release: 2024

The role and mechanism of SUMO modification in liver disease.

Issue Release: 2024

The Hippo-YAP1/HIF-1α pathway mediates arsenic-induced renal fibrosis.

Issue Release: 2024

The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation.

Issue Release: 2024

Role of mesenchymal stem cell-derived exosomes in the regeneration of different tissues.

Issue Release: 2024

Mechanism of Zhenwu Decoction modulating TLR4/NF-κB/HIF-1α loop through miR-451 to delay renal fibrosis in type 2 CRS.

Issue Release: 2024

Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.

Issue Release: 2024

P2X7 receptor deficiency attenuates cisplatin-induced kidney injury via inhibiting NLRP3 inflammasome activation.

Issue Release: 2024

Hirsutella sinensis polysaccharides and Parabacteroides goldsteinii reduce lupus severity in imiquimod-treated mice.

Issue Release: 2024

Crohn\'s disease-associated IgA nephropathy may prone to better renal outcome.

Issue Release: 2024

Gut microbiota dysbiosis in hyperuricaemia promotes renal injury through the activation of NLRP3 inflammasome.

Issue Release: 2024

The hydrogen sulfide donor 4-carboxyphenyl-isothiocyanate decreases blood pressure and promotes cardioprotective effect through reduction of oxidative stress and nuclear factor kappa B/matrix metalloproteinase (MMP)-2 axis in hypertension.

Issue Release: 2024

Galectin-3: action and clinical utility in chronic kidney disease.

Issue Release: 2024

CYP2E1 mediated advanced oxidation protein products exacerbate acetaminophen induced drug-derived liver injury in vitro and in vivo.

Issue Release: 2024

What is the Evaluation Process for Living Donors?

How Can NSAID-Induced Renal Damage Be Prevented?

How is Electrolyte Imbalance Diagnosed?

How is AKI Diagnosed?

How is Thromboembolism Related to Renal Disorders?

How important is regular monitoring for individuals with diabetes?

What Causes Nephrotic Syndrome?

When Should You Seek Medical Advice?

What Are the Common Imaging Tests for Renal Disorders?

What Affects Glomerular Filtration Rate?

Partnered Content Networks

Relevant Topics